Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco. Over the past two years, the life sciences industry has seemingly fully embraced ...

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder. Lykos ...

The technology is part of a larger platform that provides a variety of AI-powered services. As people in the industry become more comfortable with the technology, AI is being used to find potential ...

Johnson & Johnson (J&J) announced that it has acquired Intra-Cellular Therapies, a biopharmaceutical company. According to the company, the acquisition includes Caplyta (lumateperone), a once-daily ...

The digital transformation of the pharmaceutical industry continues to provide innovative ways to improve the clinical research process. With the growing importance of strategies like real-time data ...

The Healthcare Businesswomen’s Association (HBA) announced that it has named Reshema Kemps-Polanco, executive vice president and chief commercial officer at Novartis US, as its Woman of the Year. 1 ...

John Hood, CEO, Endeavor BioMedicines discusses partnering with advocacy groups to increase awareness of clinical trials for idiopathic pulmonary fibrosis. PE: Are there any ongoing collaborations ...

Teva Pharmaceuticals announced two strategic collaborations to expand its biosimilar portfolio and enhance access to high-cost biologics across key markets. The first deal, which is with Formycon AG ...

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors. GSK ...